GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (OTCPK:KKPCF) » Definitions » Cyclically Adjusted PS Ratio

KKPCF (Kaken Pharmaceutical Co) Cyclically Adjusted PS Ratio : 1.92 (As of May. 31, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio?

As of today (2025-05-31), Kaken Pharmaceutical Co's current share price is $28.0919. Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $14.65. Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is 1.92.

The historical rank and industry rank for Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

KKPCF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.34   Med: 1.91   Max: 2.99
Current: 1.51

During the past years, Kaken Pharmaceutical Co's highest Cyclically Adjusted PS Ratio was 2.99. The lowest was 1.34. And the median was 1.91.

KKPCF's Cyclically Adjusted PS Ratio is ranked better than
63.69% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.115 vs KKPCF: 1.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted revenue per share data for the three months ended in Dec. 2024 was $4.226. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $14.65 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.90 1.69 1.57 1.45 -

Kaken Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.61 1.57 1.83 -

Competitive Comparison of Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


;
;

Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=28.0919/14.65
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Kaken Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=4.226/110.7000*110.7000
=4.226

Current CPI (Dec. 2024) = 110.7000.

Kaken Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 4.558 97.900 5.154
201506 5.392 98.400 6.066
201509 5.493 98.500 6.173
201512 6.044 98.100 6.820
201603 5.087 97.900 5.752
201606 6.015 98.100 6.788
201609 6.158 98.000 6.956
201612 5.577 98.400 6.274
201703 4.989 98.100 5.630
201706 5.513 98.500 6.196
201709 5.561 98.800 6.231
201712 5.936 99.400 6.611
201803 5.038 99.200 5.622
201806 5.443 99.200 6.074
201809 5.245 99.900 5.812
201812 5.624 99.700 6.245
201903 4.889 99.700 5.428
201906 5.209 99.800 5.778
201909 5.438 100.100 6.014
201912 5.884 100.500 6.481
202003 4.547 100.300 5.018
202006 4.316 99.900 4.783
202009 4.578 99.900 5.073
202012 5.092 99.300 5.677
202103 4.296 99.900 4.760
202106 4.375 99.500 4.867
202109 4.575 100.100 5.059
202112 4.446 100.100 4.917
202203 4.087 101.100 4.475
202206 3.593 101.800 3.907
202209 3.463 103.100 3.718
202212 3.709 104.100 3.944
202303 3.476 104.400 3.686
202306 3.426 105.200 3.605
202309 3.230 106.200 3.367
202312 3.395 106.800 3.519
202403 3.060 107.200 3.160
202406 3.054 108.200 3.125
202409 6.117 108.900 6.218
202412 4.226 110.700 4.226

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kaken Pharmaceutical Co  (OTCPK:KKPCF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co Headlines